LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection
- PMID: 12909473
- DOI: 10.1016/s1053-2498(02)00645-9
LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection
Abstract
Introduction: Patients who have ventricular assist devices (VADs) and experience bloodstream infection (BSI) have high mortality. We addressed 2 questions raised by the United Network for Organ Sharing (UNOS) priority policy for this problem: 1) Are organs wasted on this ultra-high-risk group? 2) Can device-related BSI be differentiated from transient BSI?
Methods: Patients with VADs who underwent heart transplantation from 1987 to 2001, who had BSI during VAD support, and who had positive cultures at VAD explant (device-related BSI, n = 10) were compared with those with negative cultures at explant (non-device-related BSI, n = 11).
Results: Patients with device-related BSI had an 80% (8/10) rate of persistent bacteremia; 30 days and 1 year after transplantation, mortality was 14% and 26%, respectively. Non-device-related BSI (n = 11) persisted in 18% (2/11); peri-operative and 1-year mortalities were 9% and 13%. Duration of VAD support predicted infection (132 vs 48 days, p < 0.001); hypo-albuminemia (2.9 +/- 0.5 mg/dl vs 3.3 +/- 0.8 mg/dl, p < 0.05), and a resistant organism predicted a device-related BSI. These patients had increased intubation requirements and had increased creatinine concentration during the first post-operative week, with no difference in liver function, blood loss, transfusions (packed red blood cells, fresh frozen plasma, or platelets), or hemodynamic stability vs patients with non-device BSI. Despite decreased immunosuppression, we found no difference in acute rejection events with device-related BSI. Re-infection with the pre-operative organism occurred in only 1 patient per group.
Conclusions: These data suggest that urgent (Status 1A) cardiac transplantation is effective in stable patients with device-related BSI, and these data support the current UNOS policy. However, an extra-device source of BSI should be excluded by considering the isolated organism, the baseline nutritional status, and other risk factors.
Similar articles
-
Nosocomial bloodstream infections in patients with implantable left ventricular assist devices.Ann Thorac Surg. 2001 Sep;72(3):725-30. doi: 10.1016/s0003-4975(01)02888-0. Ann Thorac Surg. 2001. PMID: 11565648
-
Left ventricular assist device-related infection: treatment and outcome.Clin Infect Dis. 2005 Apr 15;40(8):1108-15. doi: 10.1086/428728. Epub 2005 Mar 11. Clin Infect Dis. 2005. PMID: 15791509
-
Bloodstream infections in mechanical circulatory support device recipients in the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support Registry: Epidemiology, risk factors, and mortality.J Heart Lung Transplant. 2018 Aug;37(8):1013-1020. doi: 10.1016/j.healun.2018.04.006. Epub 2018 Apr 25. J Heart Lung Transplant. 2018. PMID: 29936085
-
How does successful bridging with ventricular assist device affect cardiac transplantation outcome?Interact Cardiovasc Thorac Surg. 2011 Oct;13(4):405-9. doi: 10.1510/icvts.2011.273722. Epub 2011 Jul 25. Interact Cardiovasc Thorac Surg. 2011. PMID: 21788304 Review.
-
The Importance of the Management of Infectious Complications for Patients with Left Ventricular Assist Device.Healthcare (Basel). 2015 Aug 26;3(3):750-6. doi: 10.3390/healthcare3030750. Healthcare (Basel). 2015. PMID: 27417794 Free PMC article. Review.
Cited by
-
Heart transplantation using a donor heart with repaired tetralogy of Fallot: a case report.Eur Heart J Case Rep. 2023 Nov 15;8(1):ytad557. doi: 10.1093/ehjcr/ytad557. eCollection 2024 Jan. Eur Heart J Case Rep. 2023. PMID: 38192270 Free PMC article.
-
[Infection control measures and surveillance of patients with ventricular assist devices].Anaesthesist. 2007 May;56(5):429-36. doi: 10.1007/s00101-007-1155-3. Anaesthesist. 2007. PMID: 17431552 Review. German.
-
Managing drugs and devices in patients with permanent ventricular assist devices.Curr Treat Options Cardiovasc Med. 2007 Aug;9(4):318-31. doi: 10.1007/s11936-007-0027-0. Curr Treat Options Cardiovasc Med. 2007. PMID: 17761117
-
A novel approach to reduce catheter-related infection using sustained-release basic fibroblast growth factor for tissue regeneration in mice.Heart Vessels. 2007 Jul;22(4):261-7. doi: 10.1007/s00380-006-0967-4. Epub 2007 Jul 20. Heart Vessels. 2007. PMID: 17653521
-
Cardiovascular implantable device infections.Curr Infect Dis Rep. 2011 Aug;13(4):333-42. doi: 10.1007/s11908-011-0187-7. Curr Infect Dis Rep. 2011. PMID: 21484218
MeSH terms
LinkOut - more resources
Full Text Sources
Medical